Tag Archives: University of Maryland

Modulight Spotlights: LASER-SHARP RESEARCH – March 2024

March 7, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – March 2024 Glioblastoma is the most aggressive type of brain tumor. It is hard to treat because of its invasion into functioning brain tissues, limited drug delivery due to blood-brain-barrier, and evolved treatment resistance. To address these challenges, a light-activated nanoformulation, called nanoVP, was developed for glioblastoma in a new study co-led by John Quinlan and Collin Inglut in Dr. Huang’s team at the University of Maryland. Published in a prestigious journal Advanced Science, this novel therapy resulted in an improved tumor control and survival Continue reading →

Light penetration depth in brain with different photosensitizers

October 28, 2021 by Modulight Content
No comments
  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →